Taken together, our findings suggest that miR‐138, GIT1 and SEMA4C could be novel and good targets for the development of not only anti‐proliferation, but also anti‐EMT strategies in the treatment of NSCLC. This evidence concerns the gene SEMA4C and non-small cell lung carcinoma.